袁纪军

袁纪军博士

  • 苏州艾博生物科技有限公司执行副总裁

袁纪军博士先后攻读于复旦大学生命科学院生物化学系、美国俄亥俄州立大学分子生物学/生物化学系,美国加利福尼亚大学洛杉矶分校,主要研究方向为药物靶点的结构及功能研究。回国后袁纪军博士就职于上海恒瑞医药有限公司,负责生物药物的研发工作,治疗领域涉及肿瘤、糖尿病、心血管疾病等。负责的 PD-1 抗体药物项目是国内第一个申报临床试验的同类创新药物,目前该抗体药物已经在国内上市并销售。2015 年加入上海吉凯基因化学技术有限公司担任副总裁兼研发总监,负责整个集团的研发工作。2016 年成立上海吉倍生物技术有限公司,专注于细胞治疗、基因治疗、抗体药物等全新药物的研发,期间完成了 7 个创新药物知识产权的转让,转让方包括国内外上市公司,转让交易总金额超过了 10 亿人民币,同时获得了两项细胞治疗产品的临床批件。2022年初,袁纪军博士加入苏州艾博生物科技有限公司,担任执行副总裁,负责肿瘤领域临床前项目的研发工作。截止目前,袁纪军博士共发表文章 15 篇,申请专利 74 项,先后承担了 1 个国家重点专项项目及 7 个地方重点专项项目,并参与了由中国工程院牵头的《中国制造业重点领域技术创新绿皮书》的撰写。

CHENG Hoi Lok 郑凯乐

Hoi Lok Cheng Ph.D.

  • VectorBuilder CDMO Application Scientist

Hoi Lok received his BEng of Applied Chemistry from Osaka University, Japan, and his PhD from the Faculty of Biomedical Engineering, NUS, Singapore. With many years of academic research training on organic chemistry and molecular biology, he later worked on several post-doctoral projects including artificial oligonucleotide xenobiology, small binding proteins, commercial neutralizing assay development etc. in A*STAR, Singapore and SMART, Singapore.

After joining the VectorBuilder team, Hoi Lok accumulated substantial expertise in CMC of plasmid DNAs and viral vectors, as well as in GMP and corresponding regulatory guidelines from global authorities. Having facilitated multiple IND-enabling projects, Hoi Lok is now responsible for VectorBuilder’s CDMO R&D, technical support, business development, and project management.

WU Howard

Dr. Howard Wu

  • Co-founder and CEO/CSO of Full Circles Therapeutics

Howard (Hao) Wu has almost 20 years’ experience in gene editing technology and new drug discovery. He is specialized in overseeing R&D programs, new lab and research team set up in the biotech start-ups.

Dr. Wu is the co-founder and CEO/CSO of Full Circles Therapeutics, where he is dedicated to developing curative gene editing based gene/cell therapy. He is responsible for generating revenue through collaboration with MNC and biotech partners. Before founding Full Circles Therapeutics,  Dr. Wu was leading multiple discovery biology programs and disease prioritization in the genetic disease space at Fulcrum Therapeutics Inc. (NASDAQ:FULC), a Cambridge small molecule drug discovery biotech company. He had been with the company through the full development phases starting from the start-up, expansion, until post-IPO development, during which he led a cross-functional team for portfolio disease selection and prioritization of multiple disease programs including neuromuscular disease, cardiac disease, hematological and metabolic diseases, including two major partnership collaborations with MyoKardia and Acceleron.

Before joining Fulcrum, Dr. Wu was a senior research fellow at Whitehead institute, MIT. His research focused on neurological disorders utilizing a combination of CRISPR/Cas9 mediated genomic and epigenomic editing technology and stem cell technology. He did his PhD in Biochemistry and Structural Biology at Hongkong University of Science and Technology (HKUST) and Bachelor’s degree in Chemistry from Fudan University before he did his postdoctoral research at Johns Hopkins University School of Medicine and Howard Hughes Medical Institute. Dr. Wu has more than 30 journal publications, patents, and research and industry grants. For his work, he has received fellowship award from human frontier science program (HSFP) and NARSAD young investigator award.  He was also awarded the Alfred Blalock Young Investigator Award from JHMI and President’s award from Whitehead Institute, MIT.

NG Billy Wai-Lung 吳濰龍

Dr. Ng Billy Wai-Lung

  • Assistant Professor, School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong

Professor Ng’s research interests are chemical biology, drug discovery, and medicinal chemistry. The Ng lab (School of Pharmacy, the Chinese University of Hong Kong) uses chemical and biological tools to develop novel small molecules for the treatment of various diseases, including cancers, infectious and neurodegenerative diseases. He has co-authored more than 30 papers in prestigious journals such as Science, Nature Chemical Biology, Molecular Cell, J. Am. Chem. Soc., Angew. Chem. Int. Ed., and ACS Central Science and also serves as a reviewer for more than 30 journals including Science Translational Medicine, Nature Chemical Biology, and Nature Communications.

Professor Ng obtained his B.Sc. degree in Chemistry (1st Class Hons.) and Ph.D. in Organic Chemistry from the Chinese University of Hong Kong. During his graduate study, he was a Fulbright Scholar at Massachusetts Institute of Technology (MIT), under the generous funding supports from the Lee Hysan Foundation and the Fulbright Program. From 2014 – 2016, he joined the University of Oxford as a Croucher Foundation Postdoctoral Fellow. He was then recruited to Harvard Medical School / Dana-Farber Cancer Institute as a research fellow from 2016 – 2019. He was honored as a Young Global Leader (2022) by the World Economic Forum. His research has been funded by diverse sources, including the Bill & Melinda Gates Foundation, US National Academy of Medicine (NAM), the Innovation and Technology Fund (ITF), and Research Grants Council (RGC) of Hong Kong.

SANG Wei 桑偉

Mr. Sang Wei

  • 華為雲亞太區大數據&AI 總經理

桑偉先生是華為資深專家,自1998年加入華為以來,參與了多個重要的產品項目和行業解決方案的設計和推廣,曾任產品開發工程師、產品總經理、區域產品營銷部長、行業解決方案高級總監和終端雲海外產品中心部長等重要職務,在行業大數據和AI領域有長達十餘年的從業經驗。

袁纪军

袁纪军博士

  • 苏州艾博生物科技有限公司执行副总裁

袁纪军博士先后攻读于复旦大学生命科学院生物化学系、美国俄亥俄州立大学分子生物学/生物化学系,美国加利福尼亚大学洛杉矶分校,主要研究方向为药物靶点的结构及功能研究。回国后袁纪军博士就职于上海恒瑞医药有限公司,负责生物药物的研发工作,治疗领域涉及肿瘤、糖尿病、心血管疾病等。负责的 PD-1 抗体药物项目是国内第一个申报临床试验的同类创新药物,目前该抗体药物已经在国内上市并销售。2015 年加入上海吉凯基因化学技术有限公司担任副总裁兼研发总监,负责整个集团的研发工作。2016 年成立上海吉倍生物技术有限公司,专注于细胞治疗、基因治疗、抗体药物等全新药物的研发,期间完成了 7 个创新药物知识产权的转让,转让方包括国内外上市公司,转让交易总金额超过了 10 亿人民币,同时获得了两项细胞治疗产品的临床批件。2022年初,袁纪军博士加入苏州艾博生物科技有限公司,担任执行副总裁,负责肿瘤领域临床前项目的研发工作。截止目前,袁纪军博士共发表文章 15 篇,申请专利 74 项,先后承担了 1 个国家重点专项项目及 7 个地方重点专项项目,并参与了由中国工程院牵头的《中国制造业重点领域技术创新绿皮书》的撰写。

ZHU YeQing

Mr. Zhu YeQing

  • Chairman of the Board and CEO, New Horizon HealthCouncil Member, China Cancer FoundationHonorary Vice Chairman, Zhejiang Provincial Bridge Association

Co-founder of New Horizon Health (6606.HK), Mr. Zhu is the Chairman of the Board and CEO of New Horizon Health, transforming the organization into one of the most recognized bio-tech companies in China. In Feb. 2021, New Horizon Health became the first Chinese cancer screening company successfully listed on the main board of HK Exchange.

Mr. Zhu led New Horizon Health through the development, clinical trail, regulatory approval, and commercialization of Pupu tube ®, ColoClear ® and UU tube ®. ColoClear® is the first and only cancer screening test received NMPA approval as well as the first and only colorectal cancer screening test recommended by China national colorectal cancer prevention and diagnostic guidelines. UU Tube® is the first NMPA-approved consumer self-testing product for H.Pylori and Pupu Tube® is the first NMPA-approved consumer self-testing product for FIT (fecal immunochemical test), a screening test for colon cancer.

Before joining New Horizon Health, Mr. Zhu served as the Managing Director of GE Capital Asia and held multiple leadership positions in GE China and Samsung C&T.

Mr. Zhu holds a Bachelor of Science degree in biology and earned his MBA degree both from Beijing University.

CHEUNG Louis 张业炘

Mr. Cheung Louis

  • CEO, JS Biosciences

张业炘先生于2011年加入健顺生物,负责健顺生物细胞培养基板块的运营和研发管理,现任健顺生物首席执行官(CEO)。在药物研究与生产的细胞培养基开发和工艺放大等发展领域有超过20年的经验。
加入健顺生物之前,曾于美国基因泰克(Genentech)、安进(Amgen)、Medarex公司等生物制药公司任工艺开发部研究员和工程师,具有12,000升GMP生产经验,建立了提高10倍研发效能的高通量细胞培养平台,同时实践了完整的细胞营养与代谢研究分析技术。
张业炘先生拥有美国圣荷西州立大学生物化学工程硕士学位。

HU Hong-Ming, 胡红明

Hu Hong-Ming, PhD

  • Immuxell, Founder, Chairman, and CSO
    Shanghai China

Education Ph.D. in Tumor Immunology, Oregon Health and Science University, Port-land, Oregon, 2002.

M.S. in Molecular Biology, Shanghai Institute of Biochemistry,
Chinese Academy of Science, Shanghai, China, 1990.

B.S. in Biochemistry, School of Life Science,
Fudan University, Shanghai, China, 1987.

Professional Experience
Employment
Lab Chief, Laboratory of Cancer Immunobiology,
Earle A. Chiles Research Institute, Providence Medical Center, Portland, Oregon. 2003-2020.

Senior Research Associate, Laboratory of Dr. Bernard A. Fox
Earle A. Chiles Research Institute, Providence Medical Center,
Portland, Oregon. 1994-2003.

Research Associate, Laboratory of Dr. Vishva M. Dixit,
Department of Pathology, University of Michigan Medical School,
Ann Arbor, Michigan. 1991-1994.

Affiliations
ImmuXell, Founder, Chairman, and CSO 2021-
UbiVAC, CSO 2010-

Clinical adjunct professor, Department of Radiation Oncology,
Oregon Health and Science University (OHSU), Portland, Oregon.
2006-2013.

Adjunct Professor, Department of Physics,
Portland State University, Portland, Oregon. 2009-2014.

Guest Professor, School of Medicine, Xian Jiaotong University 2004-2008
Guest Professor, Shanghai Jiaotong University 2018 to 2020

Honor and Awards

American Cancer Society Research Scholar (2003-2007)